Physician profile
Eric A Perez
NPI 1366273740
$3,227.26
in general payments reported to CMS, 2019-2025
17 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $31.48 · 2024: $463 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.26 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $607.23 | 2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $530.78 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $511.19 | 2024-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $219.85 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $193.21 | 2025 | Zenpep, Vowst |
| Qol Medical, LLC | $168.40 | 2025 | Sucraid |
| Janssen Scientific Affairs, LLC | $152.52 | 2025 | Tremfya |
| Vivus LLC | $117.90 | 2025 | Pancreaze |
| Regeneron Pharmaceuticals, INC. | $92.92 | 2025 | Dupixent |
| Genzyme Corporation | $76.93 | 2025 | |
| Gilead Sciences, INC. | $75.55 | 2025 | |
| Phathom Pharmaceuticals, INC. | $69.29 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $64.83 | 2025 | Vegzelma |
| Medtronic, INC. | $51.75 | 2025 | Gi Genius |
| Mirum Pharmaceuticals, INC. | $45.87 | 2025 | Livmarli |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.64 | 2025 | Xifaxan |
| Shield Therapeutics INC | $14.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.